Symbiotec Pharmalab Limited
All news and filings related to Symbiotec Pharmalab Limited.
View all news & filings- Low impact
Symbiotec Pharmalab: Trading Window Closed Oct 1, 2026, for Q2 FY27 Results
Symbiotec Pharmalab Limited will close its trading window from October 1, 2026. This closure is to prohibit insider trading during the period leading up to the announcement of the unaudited financial results for the quarter and half-year ended September 30, 2026. The exact date for the board meeting to approve these results will be announced later.
Read the summary - Medium impact
Symbiotec Pharmalab Receives U.S. FDA EIR for Pithampur Facility with VAI Classification
Symbiotec Pharmalab Limited received an Establishment Inspection Report (EIR) from the U.S. FDA for its Pithampur, Madhya Pradesh facility. The inspection, conducted from August 10-14, 2026, resulted in a Voluntary Action Indicated (VAI) classification. This is a significant regulatory update for the company.
Read the summary - Medium impact
Symbiotec Pharmalab Q1 FY27 Earnings Call Transcript Released
Symbiotec Pharmalab released its Q1 FY27 earnings call transcript. The company discussed its API, biotech CDMO, and complex injectables businesses. It secured long-term contracts for its CDMO services and is in advanced talks for its dual-chamber vial products. Q1 FY27 consolidated revenue was ₹218 crore, with a net profit of ₹14 crore. The company targets 20% revenue and 25% EBITDA growth for FY27.
Read the summary - Low impact
Symbiotec Pharmalab: Q1 FY27 Earnings Conference Call Audio Recording Link Available
Symbiotec Pharmalab Limited has released the audio recording link for its Q1 FY27 earnings conference call held on September 22, 2026. The call discussed the company's financial and operational performance for the quarter ended June 30, 2026. The recording is available on the company's investor website.
Read the summary - Low impact
Symbiotec Pharmalab Publishes Q1 FY27 Unaudited Financial Results
Symbiotec Pharmalab Limited announced its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The results were approved by the Board on September 21, 2026, and published on September 22, 2026.
Read the summary - Medium impact
Symbiotec Pharmalab Q1FY27 Revenue at ₹218.2 Cr, PAT ₹14.1 Cr
Symbiotec Pharmalab reported Q1FY27 consolidated revenue of ₹218.2 crore, up from ₹203.2 crore in Q1FY26. Consolidated PAT decreased to ₹14.1 crore from ₹29.9 crore. The API business saw a 6% sales growth. The company filed its first ANDA for a DCV product and has significant capex planned for new revenue streams.
Read the summary - Medium impact
Symbiotec Pharmalab Q1FY27: Investor Presentation Released
Symbiotec Pharmalab released its Q1FY27 investor presentation. API revenue grew 6% to ₹215.3 crore, with EBITDA up 9% to ₹65.8 crore. Consolidated revenue increased 7% to ₹218.2 crore, while PAT declined to ₹14.1 crore due to new business expenses. The company filed its first ANDA for a DCV product and secured key CDMO agreements. Significant capex of ₹1,475 crore has been invested.
Read the summary - Medium impact
Symbiotec Pharmalab approves Q1 FY27 Unaudited Standalone & Consolidated Financial Results
Symbiotec Pharmalab Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board Meeting was held on September 21, 2026. The trading window for securities will remain closed for 48 hours post-announcement.
Read the summary - Medium impact
Symbiotec Pharmalab Declares Q1 FY27 Unaudited Standalone & Consolidated Results
Symbiotec Pharmalab Limited approved its Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The Board Meeting took place on September 21, 2026. The trading window for company securities will be closed for 48 hours post-announcement.
Read the summary - Low impact
Symbiotec Pharmalab Adopts Fair Disclosure Code Under SEBI PIT Regulations
Symbiotec Pharmalab Limited has adopted a Code of Fair Disclosure under SEBI PIT Regulations, effective December 15, 2025. The policy ensures timely and transparent disclosure of Unpublished Price Sensitive Information (UPSI) to stakeholders.
Read the summary - Low impact
Symbiotec Pharmalab Authorizes KMPs to Determine Materiality of Events
Symbiotec Pharmalab Limited has authorized its Chairman & Managing Director, CFO, and Company Secretary to determine the materiality of events and make disclosures to stock exchanges as per SEBI regulations.
Read the summary - Low impact
Symbiotec Pharmalab Adheres to SEBI Insider Trading Regulations with Updated Disclosure Code
Symbiotec Pharmalab Limited has submitted its updated Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. This action ensures adherence to fair disclosure norms for price-sensitive information.
Read the summary - Low impact
Symbiotec Pharmalab Closes Trading Window for Q1 FY27 Results
Symbiotec Pharmalab Limited has closed its trading window from September 01, 2026, until 48 hours after the declaration of Q1 FY27 unaudited financial results. The board meeting date to approve these results will be announced later.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio